Abcuro said it is adding $66 million to pursue a new path in inclusion body myositis, a rare inflammatory disorder with no approved drugs. The company plans to use the financing to support a study intended to underpin a potential biologics license application. Abcuro previously ran a Phase 2/3 program earlier this year that failed, but management highlighted positive trends in patients with less severe disease. The new effort is designed to test whether that signal can translate into a regulatory-ready outcome. The capital infusion reflects how rare-disease pipelines can remain fragile after setbacks, even when earlier subgroup trends emerge. It also underscores the emphasis on refining inclusion criteria and endpoints to recover a development strategy after Phase 2/3 failure. If the restarted study produces credible efficacy and safety, it could reposition Abcuro’s IM approach for future late-stage planning and regulatory review.